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Abstract
The mechanism by which tissue microecology influences invasion and metastasis is largely 
unknown. Recent studies have indicated differences in the molecular architecture of the metastatic 
lesion compared to the primary tumor, however, systemic analysis of the alterations within the 
activated protein signaling network has not been described. Using laser capture microdissection, 
protein microarray technology, and a unique specimen collection of 34 matched primary colorectal 
cancers (CRC) and synchronous hepatic metastasis, the quantitative measurement of the total and 
activated/phosphorylated levels of 86 key signaling proteins was performed. Activation of the 
EGFR–PDGFR-cKIT network, in addition to PI3K/AKT pathway, was found uniquely activated in 
the hepatic metastatic lesions compared to the matched primary tumors. If validated in larger study 
sets, these findings may have potential clinical relevance since many of these activated signaling 
proteins are current targets for molecularly targeted therapeutics. Thus, these findings could lead 
to liver metastasis specific molecular therapies for CRC.
Keywords
Colorectal cancer; Proteomics; Metastasis; Protein pathway activation mapping; Tumor 
microenvironment; Reverse phase protein microarray
Introduction
Colorectal cancer (CRC) is the third leading cause of cancer related deaths in the Western 
countries [1]. Approximately 35 % of patients seeking medical attention for colorectal 
cancer present with stage IV disease, and 20–50 % of the patients with stage II or III CRC 
develop metastatic lesions within 5 years from the initial diagnosis [2]. In the past two 
decades, the introduction of new molecularly targeted therapies and the improvement of 
surgical techniques has doubled the 5-year overall survival time of patients with metastases 
from 9 to 20 % [3].
Since metastasis in general, and liver metastasis specifically in CRC, is the major cause of 
death, the identification of molecular targets that are metastasis-specific is an important 
strategy to address the urgent need to improve patient survival.
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Metastatic progression is a multi-step phenomenon. It is estimated that less than 0.01 % of 
the cancer cells are able to leave the site of origin, survive in the systemic circulation, 
colonize secondary organs, and grow into a viable metastatic lesion [4]. According to 
Paget’s “Seed and Soil” theory, organ selectivity is based on a successful interaction 
between the tumor cells (seed) and the microenvironment of the secondary location (soil) 
that supports extravasation, survival, and growth of the metastatic colony [5].
To date, the analysis of metastatic tumors has focused mostly on the identification of 
genomic-based prognostic signatures of primary tumors [6–11]. Comparatively little is 
known about the protein signal pathways that mediate the interaction between the metastatic 
colony and the organ tissue microenvironment. Since signal transduction is underpinned by 
kinase-driven post-translational modifications, a direct investigation of signaling within the 
metastatic microenvironment may best be studied using proteomic technologies that can 
measure the activation state (e.g. phosphorylation) of a given protein [12–14]. The analysis 
of post-translational modifications that drive metastatic progression represents a novel 
frontier for the characterization of the molecular mechanisms underlying tumor progression 
and for the identification of molecular targets responsible for the formation of the secondary 
lesions. Such analyses are complementary to genomic studies, since gene expression has 
shown little correlation with protein expression and activation [15, 16].
This study provided a unique opportunity for broad-scale characterization of the signaling 
architecture of primary CRC compared to synchronous matched hepatic metastasis. We 
investigated whether the proteomic profile of the primary tumor and the metastatic lesion are 
homogeneous and can be used interchangeably for the selection of appropriate targeted 
treatment. Moreover, this analysis sought to identify molecular mechanisms that drive the 
metastatic progression in a host organ. We first focused on EGF receptor analysis since it is 
considered an important drug target for CRC. Not only expression but also activation status 
of the receptor was measured using the tyrosine residue 1173 due to the central role of this 
site in receptor-mediated signaling [17].
We then performed a broadened pathway activation profile of the matched set to better 
characterize molecular alterations involved in metastatic progression.
The promise of personalized therapy is the molecular fingerprint of a patient tumor that 
becomes the basis for targeted therapy. In current clinical practice, the fingerprinting is done 
on the primary tumor, not on the metastasis, which is the lethal aspect of the disease. Thus, 
we set out to explore whether the organ tissue microenvironment influences the levels of 
phosphorylated and activated signaling networks within the metastatic microenvironment 
compared to the matched primary tumor.
Materials and methods
Clinical sample collection and handling
Primary colorectal cancer tissues and matched synchronous liver metastases from 34 
untreated patients were collected at the time of surgery between 1992 and 2002. Tissue was 
obtained after Institutional Review Board approval under informed consent from the Clinica 
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Chirurgica II, Padua, Italy. Surgical specimens were coded, frozen in liquid nitrogen within 
2 h of surgical removal and stored at −80 °C until processed for molecular analysis. A board 
certified pathologist confirmed the presence of tumor in each sample. Clinical information 
and pathological characterization of the subjects enrolled in the study were collected by the 
enrolling institution.
Laser capture microdissection (LCM)
Highly enriched (greater than 90 %) CRC epithelial cell populations were obtained using 
LCM as described previously [18, 19]. Briefly, several 8 μm frozen tissue sections were 
prepared for each sample. Before LCM, sections were fixed in 70 % ethanol, stained with 
hematoxylin, and dehydrated in 70, 95, and 100 % ethanol followed by xylene. Complete 
mini protease inhibitor tablets (Roche Applied Science, Indianapolis, IN, USA) were added 
to 70 % ethanol, deionized water, and hematoxylin to avoid protein degradation. Using a 
Pixcell II Laser Capture Microdissection System (Arcturus, Mountain View, CA, USA), 
approximately 20,000 tumor epithelial cells were isolated from each sample. Isolated cells 
were lysed in a 1:1 solution of Tris–Glycine SDS sample buffer (Invitrogen, Life 
Technologies, Carlsbad, CA, USA) and Tissue Protein Extraction Reagent (Pierce, 
Rockford, IL, USA) solution supplemented with 2.5 % β-mercaptoethanol. Cellular lysates 
were boiled for 8 min and stored at −80 °C.
Reverse phase protein microarray analysis
Pathway activation mapping was performed by reverse phase protein microarray (RPMA). 
Each sample was printed onto nitrocellulose arrays in duplicate, in 5-point dilution curves to 
assure that for each endpoint a linear detection range was achieved [20–23]. All antibodies 
used in these studies were rigorously validated for single band specificity by western 
blotting prior to use [20–23]. A complete list of all endpoints measured is provided in 
Online Resource Table 1. Measured analytes were chosen based on their involvement in key 
aspects of cellular survival, mitogenesis, adhesion, motility, and inflammation. All analytes 
values were normalized to total protein concentration to ensure that changes in levels of 
protein expression/phosphorylation were not due to differences in overall protein 
concentration or spotting variances. Total protein concentration was assessed as previously 
described [24]. This method of normalization has been determined to be superior to 
normalization to any specific “housekeeping” protein [25]. Stained slides were scanned on a 
standard flatbed scanner as 16-bit images/600 dpi and spot intensities were calculated and 
normalized using Micro-Vigene| software (Vigenetech, Carlisle, MA).
Western blotting
To validate RPMA data, five matched primary tumors and synchronous liver metastases 
were randomly selected and subjected to independent LCM procurement of a separate area 
of the tumor specimen. Laser capture microdissected cells were lysed directly in SDS 
sample buffer and subjected to western blotting [26]. Blotting was performed with anti-
phospho AKT S473 (Cell Signaling, Danver, MA) and anti phospho c-KIT Y703 (Zymed 
Laboratories, Life Technologies, UK) antibodies at a 1:1,000 dilution. Intensity signals of β-
actin expression were used to normalize the total protein content in each sample. 
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Immunobands were quantified using ImageQuant v5.2 software (Molecular Dynamics, 
Sunnyvale, CA).
Statistical analysis
The correspondence between patients rank order of primary tumor and liver metastasis for 
EGFR expression and activation was evaluated using GraphPad Prism Version 5.00 
(GraphPad Software, Inc., La Jolla, CA). Only primary tumors with the highest and the 
lowest values (above the 75th and below the 25th percentile) were considered and the rank 
order of the corresponding liver metastasis was analyzed. The data obtained by RPMA 
analysis of the metastatic lesion self-organized into two major groups consisting of high and 
low intensity EGFR total and phosphorylated values. Concordance between the patient-
matched primary tumor and metastatic lesions was assessed using these data (Fig. 1).
Statistical analyses were performed on RPMA intensity values obtained using SAS version 9 
software (SAS Institute, Cary, NC). Initially, the distribution of variables was checked. If the 
distribution of variables for the analyzed groups (e.g. primary vs. metastasis) was normal, a 
two-sample t test was performed. If the variances of two groups were equal, two-sample t 
test with a pooled variance procedure was used to compare the means of intensity between 
two groups. Otherwise, two-sample t test without a pooled variance procedure was adopted. 
For non-normally distributed variables, Wilcoxon rank sum test was used. All significance 
levels were set at p = 0.05.
Results
A unique study set (Table 1) of 68 tissue samples (34 pairs) of patient-matched primary 
colorectal cancers and hepatic metastases taken at the same time of surgery was used for this 
study. To evaluate the overall concordance between the signaling networks within the 
primary tumor and its matched hepatic metastasis, the expression and activation levels of 
epithelial growth factor receptor (EGFR) were compared between matched lesions (Fig. 1). 
While only 4/18 of the patients switched from one group to another (concordance = 77.8 %) 
when measuring for total EGFR (Fig. 1, left), the concordance between the primary tumor 
and matched liver metastasis was much lower when activated/phosphorylated EGFR was 
evaluated (concordance = 55.6 %) (Fig. 1, right).
Reverse phase protein microarray based pathway mapping was then utilized to evaluate the 
activation status of 86 key signaling proteins (Online Resource Table 1) belonging to 
important cancer-related signaling networks that control motility, growth, survival, 
apoptosis, and differentiation. Our results, shown in Table 2, reveal that the level of 
expression/activation of 30 of the signaling proteins measured was significantly different 
between primary tumor and hepatic metastasis (p < 0.05). Analysis of the significant 
alterations showed that most of the differences were based on metastasis-specific elevation 
of the phosphorylation of receptor tyrosine kinases and their downstream effectors, in 
particular the activation of the PI3K/AKT pathway. The phosphorylation levels of FAK, 
PRAS, FKHR/FKHRL, and PYK2, all members of the PI3K/AKT pathway, as well as 
proteins involved in MAPK signaling, were increased in the liver metastases compared to 
the primary tumors (Table 2; Fig. 2).
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Reverse phase protein microarray findings for key signaling proteins were validated by 
western blotting. As shown by the bar graphs in Fig. 3, the phosphorylation level of AKT 
(S473) (Fig. 3, top) and c-KIT (Y703) (Fig. 3, middle) correlated well with the RPMA 
results.
Discussion
Little is known about the molecular rearrangements that cancer cells acquire either within 
the “seed” microenvironment or within the “soil”. During metastatic colonization, adaption 
to a new organ provides tumor cells with a selective pressure to acquire survival mechanisms 
through the activation of specific cellular pathways [27, 28]. Our unique study set of patient-
matched primary and synchronous metastatic lesions provided a novel opportunity to 
explore the signaling events that occur in an isogenic setting during the metastatic 
progression. The use of a powerful protein pathway mapping approach uncovered systemic 
activation of specific pathway networks elevated only in the metastatic setting in most 
patients. Understanding the molecular changes that are involved in the establishment of 
secondary lesions represents the most important step for the development of therapeutic 
strategies to specifically treat metastatic disease.
Targeting EGFR signaling using kinase inhibitors in CRC is an important standard of care 
therapy option. As part of our study, we evaluated EGFR expression and its phosphorylation/
activation in liver metastases. Indeed, we found that the overall expression and activation 
(phosphorylation) of EGFR differed between primary tumor and metastatic lesion 
(concordance of 78 and 56 % respectively). These findings are in keeping with past results 
where investigators found significant changes in the total levels of the EGFR protein in the 
metastatic lesion compared to the primary tumor [29]. These results indicate that 
measurement of EGFR and its activation/phosphorylation from the primary tumor cannot be 
used to accurately determine the level of this kinase drug target in the metastatic lesion and 
suggest that a direct sampling of the metastasis is required for accurate patient therapy 
stratification.
Genomic analysis has been conducted in the past to compare mutation status of key 
components of the EGFR pathway, such as K-Ras and B-Raf. Some studies reported a high 
correlation between the primary tumor and the metastatic lesions (95 and 97 % concordance 
respectively) [30, 31]. In contrast, Vermaat and colleagues [32], reported substantial genetic 
variability between primary tumor and patient-matched liver metastasis when a more broad 
approach for genomic analysis was used. In keeping with our protein data, they found 
significant genetic alterations in the metastatic mass that were not present in the primary 
tumor.
Beyond metastasis-specific activation of EGFR, our results reveal overarching network 
activation from other receptor tyrosine kinase (RTK) mediated signaling events within the 
metastatic lesion. Statistically significant increased phosphorylation of c-KIT, c-ABL, and 
PDGFR was observed in the metastatic cells concomitant with downstream FAK, PYK2, 
SHC, SRC, and PI3K/AKT signaling increases. AKT signaling has been shown to be a 
central player in the CRC metastatic setting as previously reported [33, 34]. Increased AKT 
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phosphorylation (on both T308 and S473) as well as a large number of AKT downstream 
substrates such as the Forkhead family, PRAS, STAT kinases were all significantly elevated 
in the metastasis compared to the primary tumor.
Aside from RTK-driven PI3K/AKT activation, we observed a greatly reduced level of PTEN 
phosphorylation (S380), which is a well-known primary control mechanism for AKT 
activation. Thus, it appears that both RTK activation and loss of AKT inhibitory mechanisms 
are major signaling events in the metastatic process. Past work has revealed a similar lack of 
concordance between AKT phosphorylation in the primary CRC tumor and matched 
metastases [35].
Due to the retrospective nature of this analysis, the sample collection protocol was not 
established a priori. Therefore, collection and freezing time might not have been consistent 
within and between subjects, although all samples were collected within 2 h. For this reason, 
cellular signaling might have been impacted by pre-analytical variables that were hard to 
control when broad pathway analysis was performed [36]. However, since we found 
systemic differences in the signaling architecture between primary and metastatic tissues 
that transcended any collection differences between patients, it does not appear that the 
variations in tissue collection time could account for the consistent pathway activation we 
found in this set. Moreover, the collection of the intra-patient primary tumor and 
synchronous metastatic lesion was random so that any collection biases would be 
normalized over the population set.
Finally, these findings are based on a relatively small cohort of patients (n = 34). A major 
factor affecting the sample size is the need to simultaneously collect patient-matched 
primary colorectal cancers and synchronous liver metastases. Collection of matched primary 
tumors and metastases is a rare event in the clinical setting, highlighting the unique nature of 
the study set that was used in this analysis. In addition, all samples were subjected to careful 
laser capture microdissection to isolate the tumor epithelium from the surrounding tissue 
prior to analysis. Tissue microarrays or similar study-sets are not commercially available and 
thus new samples will require specific prospective collection, which is ongoing.
The systemic activation of the RTK-PI3K/AKT axis in the metastatic lesion could be a cause 
or a consequence of the metastatic colonization process. The significance of the activation 
needs to be further evaluated through in vivo models. However, the systemic nature of the 
activation for so many members of a biochemically-interlinked network across a large 
number of patients highlights the probable importance of the activation of these molecular 
events.
Previous data published by our research group [26] showed that specific members of the 
signaling architecture within tumor epithelium differ between primary CRC presenting with 
synchronous liver metastasis and primary tumors that never developed secondary lesions. In 
particular, we identified the hyper-activation of the EGFR/COX2 signaling pathway in 
primary tumors from patients with advanced disease compared to the tumor epithelium from 
primary CRC from patients that remained metastasis-free. Although this previous work 
differs from our work presented herein that interrogates the signaling architecture of the 
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metastatic and primary lesions from patients with synchronous disease, the findings as a 
whole reinforce the concept that both “seed and soil” are involved in metastatic progression 
and that sequential changes at the molecular level are necessary for a tumor to disseminate 
to distant organs. According to our data, selective pathways that are activated in the primary 
tumor may promote migration and local invasion, but further molecular alterations within 
the tumor epithelium are necessary to adapt in the new “soil” in the secondary organ.
The underlying mechanisms regulating the network activation we have observed in the 
present study are unknown at this time. Recent genomic analysis of matched primary and 
metastatic CRC tumors [32] has shown that PTEN mutation changes do not correlate with 
the metastatic phenotype, thus the loss of PTEN protein expression/phosphorylation and 
associated AKT activation is not explained by mutational events alone. Given the large 
number or RTKs that were activated in the metastatic lesion (EGFR, PDGFR, c-KIT, etc.), 
much of the concomitant downstream signaling is likely to be driven by activation of these 
upstream receptors.
In conclusion, our results demonstrate that specific cell signaling pathway activations are 
associated with human CRC tumor cells that have colonized the liver. We can hypothesize 
that these pathways assist the tumor cell to survive in the new host microenvironment. If this 
hypothesis is true, then suppression of these pathways would be expected to reduce the 
growth, or kill the metastatic lesions.
Overall, these data support the need for new clinical trials in which molecularly targeted 
therapies are selected based on the metastasis-specific signaling pathways, a clinical 
approach that is supported by Vermaat and colleagues [32]. In addition, these data point to 
the importance of collecting metastatic tissue and matched primary tumors for further 
molecular profiling studies, to better understand mechanisms that drive the adaptation of 
cancer cells to a new host environment.
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Fig. 1. 
Scatter plots comparing EGFR expression (left) and EGFR Y1173 activation (right) in 
primary CRC tumors and matched liver metastasis RPMA-generated relative intensity values 
were plotted for primary tumor and matched liver metastasis. Only patients in 25th and 75th 
percentile were included in the analysis. Changes in the rank order between the two lesions 
are shown by the connecting lines. Red lines show pairs for which protein expression/
activation level switched between groups. (Color figure online)
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Fig. 2. 
Endpoints involved in the RTKs-PI3K/AKT pathway that were statistically different 
between the primary tumor and the matched hepatic lesions. a The PI3K/AKT pro-survival 
pathway and downstream substrates were statistically significantly higher in the 
synchronous liver metastases compared to the primary colon cancer. b Scatter plot of 
RPMA-generated relative intensity values for primary tumor and patient matched liver 
metastasis showing that most of the effectors involved in the PI3K/AKT pathway are more 
activated in the liver metastasis compared to the primary tumor
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Fig. 3. 
Western blot analysis RPMA data were confirmed by western blot analysis of five patient-
matched primary CRC and hepatic metastases. All samples were subjected to independent 
LCM. Blots were stained for pAKT S473, pcKIT Y703 and β-actin. The bar graphs illustrate 
the intensity value of each sample after normalization for the total amount of β-actin. 
Western blot analysis confirmed increased activation of both endpoints in the liver metastasis 
compared to the primary tumor
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Table 1
Patient clinicopathological information
Total
Number of patients
 Female 12
 Male 22
Site of primary tumor
 Right colon 7
 Transverse colon 1
 Left colon 10
 Rectum 16
T stage
 T2 5
 T3 21
 T4 8
N stage
 N0 4
 N1 15
 N2 14
 N3 1
M stage
 M+ 34
Tumor grade
 G1 2
 G2 24
 G3 8
Stage
 Stage IV 34
Clinical description of the 68 samples collected from 34 patients matched primary CRC and synchronous liver metastasis
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Table 2
Statistically significant analytes
Variable P value Regulation in liver metastases
EGFR 0.0019 ↑
p4EBP1 S65 0.0326 ↑
pAbl Y245 0.0037 ↑
pAKT S473 0.0001 ↑
pAKT T308 0.0163 ↑
pBAD S136 0.0087 ↓
pcKit Y703 0.0050 ↑
peIF4G S1108 0.0416 ↑
peNOS S1177 0.0476 ↑
pErk 1/2 T202/204 0.0021 ↑
pFADD S194 0.0222 ↑
pFAK Y576/577 0.0001 ↑
pFKHR/FKHRL1 T24/T32 0.0001 ↑
pIKBa S32/36 0.0212 ↓
pp70S6 S371 0.0006 ↓
pPDGFRβ Y751 0.0181 ↑
pPDK1 S241 0.0051 ↓
pPKC theta T538 0.0182 ↑
pPKC zeta/lambda T410/403 0.0001 ↓
pPKCα/β II T638/641 0.0017 ↓
pPRAS40 T246 0.0003 ↑
pPTEN S380 0.0001 ↓
pPyk2 Y402 0.0001 ↑
pShc Y317 0.0001 ↑
pSMAD2 S465/467 0.0043 ↑
pSrc Y527 0.0001 ↑
pSTAT3 Y705 0.0225 ↑
pSTAT5 Y694 0.0159 ↑
pVEGFR Y951 0.0001 ↑
pVEGFR2 Y1175 0.0481 ↑
List of analytes that showed a significant difference in expression/activation level between the primary CRC and synchronous liver metastases. 
Significance level was set at p = 0.05. The right column reports the class-specific trend in the hepatic lesions compared to the matched primary 
colorectal cancer. Phosphorylation site is shown when appropriate
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